Cowen ups Watson to outperform; Stellar’s Uracyst high in rationale

Cowen & Co. upgraded Watson Pharmaceuticals (NYSE:WPI) to “outperform” from “neutral,” saying it has “significantly underappreciated its brand pipeline” and making an earlier reference to the potential of Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug for painful interstitial cystitis/painful bladder syndrome. Analyst Ken Cacciatore writes that Uracyst, which is sold in Canada by Stellar and in [...]

Watson has high hopes for Stellar’s Uracyst drug

Watson Pharmaceuticals (NYSE:WPI) CEO, Paul Bisaro, painted a rosy picture of how Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug, which is indicated to treat interstitial cystitis, fills out its urology strategy. According to a presentation at a healthcare conference sponsored by Barclays Capital, Mr. Bisaro said that Watson’s strategy is based on the 10 most common [...]

Stellar outlines strategy at Cowen conference; gets Chinese patent

Upcoming milestones for Stellar Pharmaceuticals (OTCBB:SLXCF) provide for near-and mid-term investment triggers, President and CEO, Peter Riehl, said in a presentation at the SG Cowen healthcare conference in Boston. Stellar, which is only one of three Canadian companies presenting at the Cowen conference, is aggressively expanding its global out-licensing programs for its two lead products [...]